X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Kyowa Hakko Kirin Announces Phase 2 Clinical Study of RTA 402 in CKD patients with type 2 diabetes in Japan

Yuvraj_pawp by Yuvraj_pawp
23rd May 2016
in Clinical Trials

Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal Function by Inulin Clearance in a Phase II Clinical Study in Japan Kyowa Hakko Kirin Co., Ltd. announced the results of an interim efficacy analysis of a phase II clinical study (TSUBAKI study) in Japan of bardoxolone methyl*1 (RTA 402), which is a small-molecule compound in-licensed from Reata Pharmaceuticals, Inc. 

 

The clinical study is a randomized, double-blind*2, parallel group, placebo-controlled study in patients with chronic kidney disease (CKD) and type II diabetes, and has been evaluating the safety and efficacy of once-daily administration of RTA 402 for 16 weeks. Inulin clearance method*3 as the gold standard for measuring glomerular filtration rate (GFR)*4 was used in the efficacy evaluation to make a precise assessment of GFR, which is an indicator reflecting kidney function. Data from interim analysis were assessed by an Independent Data Monitoring Committee*5 and demonstrated that a significant improvement in GFR was seen in the RTA 402 compared with the placebo group. This is the world’s first result showing improvement in renal function by inulin clearance. There are no safety concerns with RTA 402. Kyowa Hakko Kirin will continue to evaluate RTA 402 toward the completion of the study.

 

Kyowa Hakko Kirin signed a license agreement with Reata for exclusive right to develop and commercialize RTA 402 in Japan, China, Taiwan, Korea and Southeast Asia on Dec. 24, 2009. Reata has been conducting a Phase II clinical study on RTA 402 in pulmonary hypertension in the US, and its initial positive data were presented at the annual meeting of the 2015 American College of Chest Physicians (CHEST). Reata is proceeding into a global Phase III clinical study on RTA 402 including Japan in connective tissue disease associated pulmonary arterial hypertension.

 

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

 

*1: Bardoxolone methyl Bardoxolone methyl activates Nrf2, a transcription factor that controls the production of over 250 antioxidant and detoxification proteins. Activation of Nrf2 protects tissues from inflammation by increasing cellular antioxidant content and suppressing inflammatory signaling pathways. Chronic inflammation has been shown to promote type 2 diabetes and its complications, including cardiovascular events and CKD.
*2: Double-blind study A double-blind study is where neither the doctor nor the patient know which group the patient is in, and avoids errors arising from bias, as the placebo effect, and objectively evaluates the effectiveness of medicinal drugs and procedures.
*3: Inulin clearance method There are two methods, which are the simple and standard method, for inulin clearance, and the standard method was used in this study. In the standard method, three sets of 30-min urine samples are collected after the continuous intravenous infusion of 1% inulin. Clearance is calculated by 30-min urine collection and serum concentration at the midpoint of each clearance period. Average of the three clearances is used as the clearance by the standard method.
. *4: Glomerular filtration rate (GFR) GFR is a marker of renal function and indicates the volume of filtrate through kidneys per minute. Estimated GFR (eGFR) based on the serum creatinine level is widely used to assess renal function; however, in case of need for accurate evaluation of renal function for example for kidney transplant donors, the inulin clearance method is used as it is considered the gold standard for measuring GFR
*5: Independent Data Monitoring Committee Independent Data Monitoring Committee is established by the sponsor to assess periodically the progress of this clinical study, safety data and critical efficacy variables. The committee recommends to the sponsor whether to continue, modify, or discontinue the study.

 

Previous Post

Allergan Launches IBS-D on Tract, New Online Resource to Support Patients with Irritable Bowel Syndrome

Next Post

Pharma Giant Eli Lilly Wants to Launch 20 New Drugs by 2023

Related Posts

Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials
Clinical Trials

Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

7th February 2022
Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials
Clinical Trials

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

7th February 2022
Qatar approves emergency use of Modernas COVID-19 vaccine
Clinical Trials

Moderna Starts Variant Specific Vaccine Trials After Pfizer

28th January 2022
Autism clinical trials now open on the TrialWire Platform
Clinical Trials

Autism clinical trials now open on the TrialWire Platform

10th January 2022
Takeda
Clinical Trials

Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate

4th January 2022
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China

14th December 2021
Next Post

Pharma Giant Eli Lilly Wants to Launch 20 New Drugs by 2023

Latest News

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In